[March 06, 2014] |
|
Dermatology Diagnostic Developer, MELA Sciences, to Host Q4 Conference Call Monday, March 17, 2014 at 4:30 pm ET
IRVINGTON, N.Y. --(Business Wire)--
MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind®,
an FDA approved optical diagnostic device that assists dermatologists in
melanoma diagnosis, will release its fourth quarter and full year 2013
results on Monday, March 17, 2014, after the market's close. MELA
Sciences President and CEO, Rose Crane will host a conference call that
day at 4:30pm ET to review the results and provide general business
update.
To participate in the conference call, please dial:
|
|
Domestic toll-free:
|
|
(877) 303-9205
|
|
|
International:
|
|
(760) 536-5226
|
|
|
|
|
|
|
Live Webcast & Replay: A live webcast will be
available at: www.melasciences.com/investors/home If
you are unable to participate during the live call and webcast, a replay
will be archived and available for approximately 90 days after the call.
About MELA Sciences, Inc. www.melasciences.com MELA
Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The flagship product is
MelaFind®, an FDA, PMA and CE Mark approved, non-invasive
diagnostic tool to aid dermatologists in melanoma evaluation and
diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface to
2.5 mm beneath the skin. It provides images and data on the relative
disorganization of a lesion's cell structure that provides substantial
additional perspective to aid melanoma diagnosis. MELA is also exploring
new potential uses for its core imaging technology and algorithms.
[ Back To TMCnet.com's Homepage ]
|